Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biofrontera Inc. - Common Stock (NQ: BFRI )

0.9256 -0.0144 (-1.53%)
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biofrontera Inc. - Common Stock

< Previous 1 2 3 Next >
Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
Via ACCESSWIRE
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
Via ACCESSWIRE
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference
Via ACCESSWIRE
Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024
Via ACCESSWIRE
Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update
Via ACCESSWIRE
Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024
Via ACCESSWIRE
CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
Via ACCESSWIRE
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
Via ACCESSWIRE
Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update
Via ACCESSWIRE
Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants
Via ACCESSWIRE
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
Via ACCESSWIRE
Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024
Via ACCESSWIRE
BioMedNewsBreaks – Biofrontera Inc. (NASDAQ: BFRI) Closes on Private Placement Valued at Up to $16M
Via Investor Brand Network
Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)
Via ACCESSWIRE
Biofrontera Inc. Announces Preliminary Third Quarter Revenues
Via ACCESSWIRE
Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update
Via ACCESSWIRE
Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma
Via ACCESSWIRE
Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules
Via ACCESSWIRE
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
Via ACCESSWIRE
Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules
Via ACCESSWIRE
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use
Via ACCESSWIRE
Biofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%
Via ACCESSWIRE
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023
Via ACCESSWIRE
BioMedNewsBreaks – Biofrontera Inc. (NASDAQ: BFRI) Announces $4.5M Registered Direct
Via Investor Brand Network
Biofrontera Inc. to Report Third Quarter 2023 Financial Results on November 9 and Hold Conference Call on November 10
Via ACCESSWIRE
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
Via ACCESSWIRE
Biofrontera Inc. to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference
Via ACCESSWIRE
Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts
Via ACCESSWIRE
Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)
Via ACCESSWIRE
Biofrontera Inc. to Report Second Quarter Financial Results on August 11, 2023
Via ACCESSWIRE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.